EW
Income statement / Annual
Last year (2024), Edwards Lifesciences Corporation's total revenue was $5.44 B,
a decrease of 9.41% from the previous year.
In 2024, Edwards Lifesciences Corporation's net income was $4.17 B.
See Edwards Lifesciences Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$5.44 B |
$6.00 B |
$5.38 B |
$5.23 B |
$4.39 B |
$4.35 B |
$3.72 B |
$3.44 B |
$2.96 B |
$2.49 B |
| Cost of Revenue |
$1.12 B
|
$1.38 B
|
$1.08 B
|
$1.25 B
|
$1.08 B
|
$1.11 B
|
$939.40 M
|
$875.30 M
|
$797.40 M
|
$617.20 M
|
| Gross Profit |
$4.32 B
|
$4.63 B
|
$4.30 B
|
$3.98 B
|
$3.31 B
|
$3.23 B
|
$2.78 B
|
$2.56 B
|
$2.17 B
|
$1.88 B
|
| Gross Profit Ratio |
0.79
|
0.77
|
0.8
|
0.76
|
0.75
|
0.74
|
0.75
|
0.75
|
0.73
|
0.75
|
| Research and Development Expenses |
$1.05 B
|
$1.07 B
|
$945.20 M
|
$903.10 M
|
$760.70 M
|
$752.70 M
|
$622.20 M
|
$552.60 M
|
$443.30 M
|
$383.10 M
|
| General & Administrative Expenses |
$0.00
|
$1.82 B
|
$1.57 B
|
$1.49 B
|
$0.00
|
$0.00
|
$1.09 B
|
$984.70 M
|
$904.70 M
|
$850.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$1.20 M
|
$1.10 M
|
-$300,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.79 B
|
$1.82 B
|
$1.57 B
|
$1.49 B
|
$1.23 B
|
$1.24 B
|
$1.09 B
|
$984.70 M
|
$904.70 M
|
$850.70 M
|
| Other Expenses |
$101.10 M
|
$194.50 M
|
$2.60 M
|
$12.70 M
|
$11.50 M
|
$8.20 M
|
$4.00 M
|
-$8.20 M
|
-$4.90 M
|
-$4.00 M
|
| Operating Expenses |
$2.94 B
|
$3.09 B
|
$2.51 B
|
$2.40 B
|
$1.99 B
|
$1.99 B
|
$1.71 B
|
$1.54 B
|
$1.35 B
|
$1.23 B
|
| Cost And Expenses |
$4.06 B
|
$4.47 B
|
$3.59 B
|
$3.65 B
|
$3.07 B
|
$3.11 B
|
$2.65 B
|
$2.41 B
|
$2.15 B
|
$1.85 B
|
| Interest Income |
$120.30 M
|
$67.20 M
|
$35.50 M
|
$17.40 M
|
$23.40 M
|
$11.50 M
|
$32.00 M
|
$20.30 M
|
$10.80 M
|
$7.90 M
|
| Interest Expense |
$19.80 M
|
$17.60 M
|
$19.20 M
|
$18.40 M
|
$15.80 M
|
$20.70 M
|
$29.90 M
|
$2.90 M
|
$8.40 M
|
$9.30 M
|
| Depreciation & Amortization |
$155.20 M
|
$144.90 M
|
$166.80 M
|
$163.30 M
|
$135.40 M
|
$114.60 M
|
$77.40 M
|
$81.90 M
|
$71.20 M
|
$65.80 M
|
| EBITDA |
$1.72 B |
$1.77 B |
$1.96 B |
$1.86 B |
$1.07 B |
$1.31 B |
$872.20 M |
$1.10 B |
$827.10 M |
$706.60 M |
| EBITDA Ratio |
0.32
|
0.29
|
0.34
|
0.28
|
0.4
|
0.31
|
0.37
|
0.29
|
0.3
|
0.26
|
| Operating Income Ratio |
0.25
|
0.26
|
0.32
|
0.26
|
0.37
|
0.26
|
0.2
|
0.3
|
0.26
|
0.26
|
| Total Other Income/Expenses Net |
$169.40 M
|
$64.00 M
|
$18.90 M
|
$11.70 M
|
$19.10 M
|
$19.70 M
|
$13.20 M
|
$12.20 M
|
-$45.90 M
|
-$20.30 M
|
| Income Before Tax |
$1.55 B
|
$1.60 B
|
$1.77 B
|
$1.70 B
|
$916.70 M
|
$1.17 B
|
$761.40 M
|
$1.03 B
|
$737.90 M
|
$622.40 M
|
| Income Before Tax Ratio |
0.28
|
0.27
|
0.33
|
0.33
|
0.21
|
0.27
|
0.2
|
0.3
|
0.25
|
0.25
|
| Income Tax Expense |
$152.10 M
|
$198.70 M
|
$245.50 M
|
$198.90 M
|
$93.30 M
|
$119.60 M
|
$39.20 M
|
$412.80 M
|
$168.40 M
|
$127.50 M
|
| Net Income |
$4.17 B
|
$1.40 B
|
$1.52 B
|
$1.50 B
|
$823.40 M
|
$1.05 B
|
$722.20 M
|
$622.10 M
|
$569.50 M
|
$494.90 M
|
| Net Income Ratio |
0.77
|
0.23
|
0.28
|
0.29
|
0.19
|
0.24
|
0.19
|
0.18
|
0.19
|
0.2
|
| EPS |
6.98 |
2.31 |
2.46 |
2.41 |
1.32 |
1.68 |
1.15 |
0.98 |
0.89 |
0.77 |
| EPS Diluted |
6.97 |
2.3 |
2.44 |
2.38 |
1.3 |
1.64 |
1.13 |
0.96 |
0.87 |
0.75 |
| Weighted Average Shares Out |
$597.70 M
|
$606.70 M
|
$619.00 M
|
$623.30 M
|
$622.60 M
|
$624.90 M
|
$627.60 M
|
$632.70 M
|
$639.00 M
|
$646.50 M
|
| Weighted Average Shares Out Diluted |
$599.30 M
|
$609.40 M
|
$624.20 M
|
$631.20 M
|
$631.90 M
|
$636.60 M
|
$640.80 M
|
$647.70 M
|
$653.40 M
|
$660.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
